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Background: A direct and independent role of inflammation in atherothrombosis was recently 
highlighted by the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) 
trial, showing the benefit of inhibiting signaling molecules, eg, interleukins. Accordingly, we 
sought to devise a flexible platform for preventing the inflammatory drivers at their source to 
preserve plaque endothelium and mitigate procoagulant risk.
Methods: p5RHH-siRNA nanoparticles were formulated through self-assembly processes. 
The therapeutic efficacy of p5RHH-JNK2 siRNA nanoparticles was evaluated both in vitro 
and in vivo.
Results: Because JNK2 is critical to macrophage uptake of oxidized lipids through scavenger 
receptors that engender expression of myriad inflammatory molecules, we designed an RNA-
silencing approach based on peptide–siRNA nanoparticles (p5RHH-siRNA) that localize to 
atherosclerotic plaques exhibiting disrupted endothelial barriers to achieve control of JNK2 
expression by macrophages. After seven doses of p5RHH-JNK2 siRNA nanoparticles over 
3.5 weeks in ApoE-/- mice on a Western diet, both JNK2 mRNA and protein levels were sig-
nificantly decreased by 26% (P=0.044) and 42% (P=0.042), respectively. Plaque-macrophage 
populations were markedly depleted and NFκB and STAT3-signaling pathways inhibited by 
47% (P,0.001) and 46% (P=0.004), respectively. Endothelial barrier integrity was restored 
(2.6-fold reduced permeability to circulating 200 nm nanoparticles in vivo, P=0.003) and 
thrombotic risk attenuated (200% increased clotting times to carotid artery injury, P=0.02), 
despite blood-cholesterol levels persistently exceeding 1,000 mg/dL. No adaptive or innate 
immunoresponses toward the nanoparticles were observed, and blood tests after the completion 
of treatment confirmed the largely nontoxic nature of this approach.
Conclusion: The ability to formulate these nanostructures rapidly and easily interchange or 
multiplex their oligonucleotide content represents a promising approach for controlling deleteri-
ous signaling events locally in advanced atherosclerosis.
Keywords: siRNA, JNK2, peptide nanoparticles, perfluorocarbon nanoparticles, macrophages, 
atherosclerosis, plaque, ApoE-/- mice, thrombosis, endothelium, erosions, scavenger receptors
Introduction
Atherosclerotic lesions emerge from the interplay of numerous cell types, blood 
components, hemodynamic factors, and genetic predilections that engender a 
smoldering inflammatory process exacerbated by such risk factors as hypertension, 
diabetes, and smoking.1 Among the earliest events in lesion formation is the activa-
tion of endothelial cells lining blood vessels in atherosclerosis-prone sites by complex 
mechanical and fluid shear stresses,2,3 resulting in upregulation of surface receptors for 
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adhesion molecules, such as VCAM1, that facilitate entry, 
proliferation, and differentiation of monocytes in the intima. 
The uptake of oxidized lipids (eg, oxidized low-density 
lipoprotein [oxLDL]) by polarized macrophages to form 
foam cells generates a panoply of cytokines and chemok-
ines that accelerate endothelial injury, ultimately leading to 
extensive endothelial cell sloughing,4 plaque erosion, and/or 
plaque-cap rupture that exposes the inflamed procoagulant 
milieu to acute thrombosis.5–9
Recently, we reported that plaque endothelial barrier 
disruption and procoagulant activity in ApoE-/- mice on 
a Western diet was able to be mitigated rapidly within a 
few weeks by periodic treatment with thrombin-targeted 
nanoparticles.10 These particles carry PPACK (proline– 
phenylalanine–arginine–chloromethyl ketone), an irreversible 
inhibitor of thrombin around three orders of magnitude more 
selective for factor IIa than for Xa.11 When injected systemi-
cally, the therapeutic nanostructures passively permeate dam-
aged endothelial barriers, but not normal vascular barriers, 
and are retained in the plaque intima to exert sustained 
thrombin surveillance without inducing systemic bleeding 
diathesis. Restoration of endothelial barrier function and 
abrogation of thrombotic risk were accompanied by reduc-
tions in thrombin–antithrombin complexes, tissue factor, and 
classical inflammatory drivers (ie, NFκB) in endothelium and 
macrophages in conjunction with reduced plaque burden, 
despite persistent hypercholesterolemia (.1,000 mg/dL).
Taken together with recent reports of newer antico-
agulants used to forestall atherosclerosis, and in light of the 
recent Canakinumab Antiinflammatory Thrombosis Out-
come Study (CANTOS) clinical trial reporting the benefit of 
inhibiting inflammatory drivers of atherothrombosis (IL1β) 
despite hypercholesterolemia,12 these experimental data 
prompted us to inquire if more selective and highly specific 
anti-inflammatory plaque-targeted nanoparticle formulations 
could similarly normalize endothelial barrier function and 
thrombotic risk without affecting clotting function locally 
or systemically. While thrombin is clearly a local target for 
intervention in advanced plaques, it exerts highly pleiotropic 
procoagulant and inflammatory signaling effects (via PARs) 
in advanced plaques, but also serves a physiologic function 
as a critical wound-healing molecule. Therefore, we sought 
to interdict key inflammatory signaling events at their source, 
the plaque macrophage, without affecting either clotting or 
the physiological function of thrombin itself.
Accordingly, we selected the JNK pathway as a target 
for testing a new class of recently developed therapeutic 
nanoparticles that could be used to deliver highly specific 
siRNA for JNK protein knockdown in procoagulant plaques. 
JNKs are members of the MAPK family and play a critical 
role as proapoptotic responders to a variety of environmental 
stresses, cytokines, and growth factors.13–15 JNK2, one of three 
isoforms in the JNK family (also termed “stress-activated 
protein kinases”), is a principal mediator of foam-cell for-
mation through the scavenger-receptor-signaling pathway. 
JNK2 stimulates macrophage uptake and internalization of 
oxLDL to form resident foam cells by phosphorylating scav-
enger receptors.16 The scavenger-receptor-signaling pathway 
plays a critical role in macrophage uptake of oxidized lipids 
and foam-cell formation.17 Although JNK2 represents a 
therapeutic target for suppressing atherosclerosis,13,16 there 
are no selective pharmaceutical agents that might facilitate 
elucidation of JNK-isoform activities in vivo. The immediate 
goal was to develop a specific RNA-silencing approach for 
suppressing JNK2 locally in plaques as proof of concept for 
a flexible and interchangeable platform capable of targeting 
any mRNA of interest in inflamed plaques.
RNA interference induced by siRNA is based on complete 
base-pair match with the mRNA of interest and induced 
solely by mRNA cleavage. This interference mechanism 
enables multiple mRNAs to be degraded by one siRNA and 
achieve efficient and long-lasting knockdown effects. In fact, 
cell division is the only dilution limit in siRNA-induced 
mRNA knockdown.18 Although siRNA holds great promise 
as a therapeutic approach, its clinical translation has been 
limited, due to challenges in effective delivery to the site of 
interest. Besides viral-based delivery strategies, cationic lip-
ids, polymers, and peptides are employed for siRNA delivery. 
Although cationic lipid is the best characterized and most effi-
cient delivery approach, clinical translation has been limited, 
due to its cytotoxicity19 and systemic immunoresponses.20 
The protonatable moieties of the cationic polymers, includ-
ing polyethylenimine, cyclodextrin, and polysaccharide 
chitosan,21 provide robust endosomolysis for siRNA endo-
somal escape. However, increased cytotoxicity from desta-
bilization of cell membrane and reactive oxygen-species 
production limits their clinical translation.22,23 Because of pro-
moted endocytosis and lack of cytotoxicity, cationic peptides 
have gained popularity in siRNA delivery. Unfortunately, the 
application of peptide vectors is limited by endosomal entrap-
ment and serum instability.24,25 Accordingly, we recently 
developed a novel peptide that overcomes the limitations of 
other cationic peptides, and incorporated pH-sensing resi-
dues to release siRNA and enable endosomal escape.26–28
We report herein the application of this flexible peptide-
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anti-JNK2 sirNa nanoparticles for atherosclerosis
JNK2 in atherosclerotic plaques of ApoE-/- mice on a Western 
diet. We describe an engineered 21-amino acid, amphipathic, 
cationic peptide (p5RHH) that condenses oligonucleotides 
into a 55 nm particle in a simple mixing procedure ready 
for injection. These nanostructures produce no measurable 
innate or adaptive immunoresponses and no apparent organ 
toxicity. We show that p5RHH-JNK2 siRNA nanoparticles 
rapidly penetrate disrupted plaque endothelial barriers to 
downregulate local JNK2 expression, resulting in attenua-
tion of vessel-procoagulant activity, recovery of endothelial 
barrier integrity, and reduction in plaque macrophages after 
sequential dosing for ,1 month. Additionally, we demon-
strate that JNK2 silencing reduces plaque inflammation in 
part by inhibiting NFκB and STAT3 signaling.
Methods
p5rhh-sirNa-nanoparticle preparation
Peptide structures for condensation of siRNA into 55 nm 
particles have been described in prior publications.26,27 
p5RHH peptide was synthesized by GenScript and siRNAs 
with or without fluorescence labeling were ordered from 




pared at 20 mM in molecular biology-grade water (46-000-CI; 
Corning, New York, NY, USA), while siRNAs were prepared 
at 100 µM in siRNA buffer diluted from 5× siRNA buffer 
(B-002000-UB-100; Thermo Fisher Scientific, Waltham, 
MA, USA). The peptide:siRNA mole ratio was 100:1. For 
in vitro applications, p5RHH-siRNA nanoparticles were for-
mulated by mixing p5RHH and siRNA in Hanks’ Balanced 
Salt solution (HBSS) (14025-092; Thermo Fisher Scientific) 
and incubated at 37°C for 40 minutes, followed by albumin 
stabilization, as previously reported.27 For in vivo studies, 
peptide and siRNA mixtures in HBSS were incubated on ice 
for 10 minutes prior to intravenous (IV) injection with 0.5 mg 
siRNA/kg. Physical characterizations of albumin-coated 
p5RHH-siRNA nanoparticles showed a particle size of 55 nm 
with polydispersity of 0.282 and ζ-potential of -33.24 mV.
Perfluorocarbon-nanoparticle formulation
Perfluorocarbon (PFC) nanoparticles were produced using 
previously described methods.29 Briefly, a lipid mixture of 
99 mol% 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 
1 mol% 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine 
(850355P and 850705P, respectively; Avanti Polar Lipids, 
Alabaster, AL, USA) was prepared in a chloroform–methanol 
mixture (3:1 v:v). The solvents were then evaporated to 
generate a lipid film that was dried overnight in a vacuum 
oven at 50°C. The lipid film (2.0% w:v), perfluoro-15-
crown-5-ether (CE; 20% w:v; Gateway Specialty Chemicals, 
St Peters, MO, USA), and Milli-Q water were sonicated and 
emulsified for five passes at 20,000 psi (138,000 kPa) in an 
ice bath (LV-1; Microfluidics, Newton, MA, USA). The 
emulsion was modified to replace the crown ether core with 
perfluorooctyl bromide (PFOB) for use as a 19F magnetic 
resonance spectroscopy (MRS) reference standard for quan-
tification of nanoparticle concentration in plaques.
cell culture
Mouse monocytic RAW 264.7 cells (Washington University 
Tissue Culture Support Center, St Louis, MO, USA) were 
maintained in DMEM (30-2001; ATCC, Manassas, VA, 
USA) with 10% v:v heat inactivated fetal bovine serum (FBS) 
(F2442; Sigma-Aldrich) in a humidified environment with 
5% CO
2
. RAW 264.7 cells were seeded in six-well plates 
and maintained in the aforementioned culture conditions 
for 24 hours before p5RHH-siRNA-nanoparticle treatment. 
p5RHH-siRNA nanoparticles were formulated and incu-
bated with RAW 264.7 cells at siRNA concentration of 
50 nM for 4 hours. Then, cells were washed twice with PBS 
(14040117; Thermo Fisher Scientific) and incubated with the 
aforementioned culture medium for another 24–72 hours, 
before reverse-transcription polymerase chain reaction 
(RT2-PCR) or Western blot.
confocal imaging
RAW 264.7 cells were cultured on glass coverslips and 
treated with p5RHH-siRNA nanoparticles generated by 
using Cy3-labeled siRNA (Sigma-Aldrich). At 48 hours after 
treatment, cells were washed three times in PBS with Ca2+ 
and Mg2+ and fixed in 4% paraformaldehyde (157-4-100; 
Electron Microscopy Sciences, Hatfield, PA, USA) before 
being mounted on glass slides using mounting medium 
with 4′,6-diamidino-2-phenylindole (H-1200; Vector Labs, 
Burlingame, CA, USA). Cells were imaged with confocal 
microscopy (Meta 510; Carl Zeiss, Oberkochen, Germany).
Two-photon imaging
ApoE-/- mice fed a Western diet for 3.5 months received IV 
injections of p5RHH-Cy3-labeled siRNA nanoparticles or 
control nanoparticles without fluorescence labeling and were 
euthanized 24 hours later to collect aortas. En face imaging 
of aorta samples was performed on a custom-built video-rate 
two-photon microscope equipped with a Chameleon Vision 
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ApoE-/- mice fed a Western diet for 3.5 months received IV 
injections of p5RHH-Cy5.5-labeled siRNA nanoparticles 
or control nanoparticles without fluorescence labeling. 
At 24 hours after injection, aortas were collected for ex vivo 
IVIS imaging (Xenogen IVIS Spectrum; PerkinElmer, 
Waltham, MA, USA). The following settings were used for 
image acquisition: excitation 675 nm, emission 720 nm, bin-
ning factor 8, field of view 12.9, exposure time 0.5 seconds, and 
f-value 2. The pseudocolor “efficiency image” was presented 
to illustrate fluorescence-labeled nanoparticle distribution 
in the aortas. Fluorescence data were calibrated quantita-
tively in units of radiant efficiency or photon flux per unit 
excitation intensity (photons/sec/cm2/steradian)/(µW/cm2).
real-time Pcr
Total RNA from RAW 264.7 cells or aortas was isolated 
using an RNeasy minikit (74104; Qiagen, Venlo, the 
Netherlands). RNA (1 µg) was used to synthesize cDNA by 
reverse transcription with an RT2 first-strand kit (330401; 
Qiagen). Real-time PCR analysis was performed on an ABI 
7300 system (Thermo Fisher Scientific) with RT2 first SYBR 
green/ROX PCR master mix (330530; Qiagen). Specific 
primers for each gene were purchased from Qiagen. Genes 
of interest were normalized to mouse β-actin.
Western blot
Radioimmunoprecipitation assay (RIPA) buffer (R0278-
500ML; Sigma-Aldrich) with protease inhibitors (4906837001; 
Sigma-Aldrich) per 10 mL RIPA buffer and phenylmethyl-
sulfonyl fluoride (8553; Cell Signaling Technology, Danvers, 
MA, USA) at a final concentration of 1 mM was used to 
extract proteins from RAW 264.7 cells or aortas. Briefly, cells 
were disrupted and sonicated in the aforementioned buffer 
and protein lysates obtained by centrifugation for 10 minutes 
at 12,000× g at 4°C. For the aortas, homogenization was per-
formed with a Bullet Blender Storm (Next Advance, Troy, 
NY), followed by the same centrifugation. Protein concentra-
tion was quantified with BCA protein assay (23225; Thermo 
Fisher Scientific). Under reducing conditions, equivalent 
amounts of total protein were fractionated using sodium dode-
cyl sulfate polyacrylamide-gel electrophoresis. Membranes 
were probed with rabbit anti-JNK2 or anti-STAT3 (1:1,000 
dilution, 4,672S or 12,640S, respectively; Cell Signaling 
Technology) and rabbit anti-GAPDH (1:1,000 dilution, 
sc-25778; Santa Cruz Biotechnology, Dallas, TX, USA). 
Membranes were washed and incubated with secondary 
antibody antirabbit HRP (1:10,000 dilution, sc-2313; Santa 
Cruz Biotechnology). Bands were visualized with Pierce ECL 
Western blotting substrate (32106; Thermo Fisher Scientific) 
using ChemiDoc MP (Bio-Rad Laboratories, Hercules, CA, 
USA). Knockdown of proteins was quantified using ImageJ 
(National Institutes of Health, Bethesda, MD, USA).
Foam-cell-formation assay
At 48 hours after p5RHH-JNK2 siRNA-nanoparticle 
treatment, RAW 264.7 cells were treated with or without 
50 µg/mL acetylated LDL (acLDL; RP-045; Intracel 
Resources, Frederick, MD, USA) for an additional 24 hours. 
To visualize foam-cell formation, RAW 264.7 cells under-
went oil red O staining as previously published.27
Immunofluorescence imaging
Aortas were embedded in optimal cutting-temperature 
compound before sectioning and staining. Briefly, the fro-
zen aorta sections of 8 µm were fixed in acetone at -20°C 
for 20 minutes before incubation with rabbit anti-JNK2 
(1:200 dilution, ab76125, Abcam, Cambridge, UK), rat anti-
monocyte+ macrophage (Moma2; 1:200 dilution, ab33451; 
Abcam), or rabbit anti-NFκB p65 (D14E12) XP (1:200 
dilution, 8242; Cell Signaling Technology), followed with 
incubation in appropriate secondary antibodies: goat pAb to 
rabbit IgG (DyLight 488; 1:500 dilution, ab96899; Abcam) 
or goat pAb to rat IgG (Alexa Fluor 594; 1:500 dilution, 
ab150160; Abcam). All images were acquired using an 
Olympus microscope at the same exposure times and ana-
lyzed with ImageJ. The percentage of acellular (anucleate) 
area in plaques was evaluated in blinded fashion by an 
experienced reviewer (HY) in these same aorta sections in 
mice with or without treatment based on regions of interest 
segmented in semiautomated objective fashion with the use 
of ImageJ to select all regions devoid of blue-counterstained 
nuclei. This method was consistent with what has been 
reported, and yielded comparable percentile ranges for plaque 
acellular compartments in ApoE-/- mice.30
atherosclerosis induction and treatment
Male ApoE-/- mice (4–6 weeks old; Jackson Laboratory, 
Bar Harbor, ME, USA) were fed a Western diet (TD.88137; 
Envigo, Huntingdon, UK) for 14 weeks before treatment with 
p5RHH-JNK2 siRNA nanoparticles at 0.5 mg siRNA/kg or 
HBSS via tail-vein injection for 3.5 weeks, with a total of 
seven doses. During treatment, all mice were maintained on the 
Western diet. Animals were killed 24 hours after the final dose.
carotid-artery thrombosis methodology
To define vessel-procoagulant activity, mice were anes-
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anti-JNK2 sirNa nanoparticles for atherosclerosis
87 mg/kg, respectively), and for carotid-artery photochemical 
injury, to measure the time required for vessel occlusion, as 
previously reported.10,31,32 Time to occlusion was recorded 
and used as a quantitative index of procoagulant activity and 
global thrombotic risk. Detailed methodology is included in 
Figure S1.
19F MRS quantification of nanoparticle 
deposition in aortic plaques
19F MRS of isolated whole aortas was measured by using a 
Varian 11.7 T scanner with an in-house-designed solenoid 
radiofrequency coil and procedures as published previously.33 
Aortas were placed in centrifuge tubes and measured together 
with an internal standard of 0.1% PFOB nanoparticles. 
19F MRS (flip angle 90°, number of averages 2,048 (aortas) 
using spin-echo sequence) was recorded for quantitative 
evaluation of PFC (crown ether) nanoparticle accumulation 
in the aortas. The crown ether 19F signal was compared with 
the distinct 19F signal of the PFOB standard containing a 
known concentration of 19F atoms. The calibrated crown 
ether nanoparticle amount was normalized to the weight of 
the aorta sample and expressed as picoliters per milligram 
(pL/mg), representing the content of PFC nanoparticles taken 
up by aortic plaques.
Compared to static endothelial staining methods for 
vascular barrier assessment, the use of semipermeating 
PFC nanoparticles with 250 nm diameter in vivo circulat-
ing provides a selective and functional metric for evaluating 
endothelial barrier damage in the atherosclerotic plaques, 
as these PFC nanoparticles do not penetrate vessels without 
missing endothelium. Moreover, these PFC nanoparticles 
do not register endothelial dysfunction with tight-junction 
weakening, and instead are specific to stages of atheroscle-
rosis with plaque endothelial disruption, which correlates 
with procoagulant activity directly.32 Quantitative measure-
ment based on 19F spectroscopy is objective, because a 
full aortic sample is used. Therefore, it is not subjective to 
selection bias.
hematologic parameters and serum 
chemistry
Blood was collected from left ventricles and evaluated for 
blood counts and serum chemistry. All tests were done at 
the Department of Comparative Medicine, Washington 
University.
splenic cell-subpopulation analysis
Spleens were collected and dissociated mechanically to 
get single-cell suspensions. R-phycoerythrin-conjugated 
anti-CD25 (561065, PC61; BD Biosciences, San Jose, CA, 
USA), R-phycoerythrin-conjugated anti-NK1.1 (12-5941-63, 
PK136; Thermo Fisher Scientific), fluorescein isothiocya-
nate- or peridinin–chlorophyll–protein complex-conjugated 
anti-CD4 (550280, L3T4; BD Biosciences), fluorescein 
isothiocyanate-conjugated anti-CD19 (550284, 1D3; BD 
Biosciences), peridinin–chlorophyll–protein complex- or 
allophycocyanin-conjugated anti-CD8 (553032, 53-6.7; 
BD Biosciences), and Gr1 (14-5931-81, Ly-6G; Thermo 
Fisher Scientific) were used. Briefly, 106 cells were used 
and blocked in the anti-FcR monoclonal antibody 2.4 G
2
, 
followed with staining by incubation with the indicated 
antibodies at 4°C for 20 minutes. Cells were then washed 
and resuspended before flow-cytometry analysis. A FoxP3 
staining kit (71-5775; Thermo Fisher Scientific) was used 
to investigate FoxP3 expression. A FACSCalibur cell 
analyzer was used for flow-cytometry evaluations and Cell-
Quest Pro software used for data analysis (BD Biosciences).
Purification and stimulation of CD4+ 
T cells
To isolate CD4+ T cells from mouse spleens, positive mag-
netic sorting was performed using an AutoMACS separator 
(130-104-454, MACS CD4+ microbeads; Miltenyi Biotech, 
Bergisch Gladbach, Germany). Fluorescence-labeled anti-
CD4, anti-CD8, and anti-CD19 monoclonal antibodies (BD 
Biosciences) were used to verify isolated CD4+ popula-
tion purity using flow cytometry. After purification, 2×106 
cells/mL CD4+ T cells were resuspended in RPMI 1640 
supplemented with 1% v:v NEAA, 10% v:v FBS, 2 mM 
l-glutamine, 1% v:v sodium pyruvate, 10 mM HEPES, 
100 µg/mL streptomycin, 50 µM 2-mercaptoethanol, and 
100 U/mL penicillin, then seeded at 2×105 cells/well in flat-
bottomed 96-well microtiter plates coated with 5 µg/mL anti-
CD3 monoclonal antibody (555273; BD Biosciences). Cells 
were cultured for 72 hours, before collection of culture super-
natants for cytokine evaluations using BD cytometric bead 
arrays (552364 mouse inflammation kit; BD Biosciences).
complement activation
Mice received IV injections of p5RHH-JNK2 siRNA nanopar-
ticles at 0.5 mg siRNA/kg. At 30 minutes postinjection, blood 
was drawn from the inferior vena cava. To prevent further 
ex vivo complement activation, blood was transferred imme-
diately into tubes with 10 mM EDTA to get fresh plasma, 
which was used for C3a enzyme-linked immunosorbent assay 
(ELISA).34 Briefly, rat antimouse C3a (4 µg/mL) monoclonal 
antibody (558250; BD Biosciences) was used to coat plates by 
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at room temperature for 1 hour) and washing (three times with 
0.05% v:v Tween 20 in PBS), plates were incubated with 100 
µL freshly collected 1:100-diluted plasma samples at room 
temperature for 1 hour. Plates were then washed three times 
and incubated with biotinylated antimouse C3a at 250 ng/
mL at room temperature for 1 hour. Plates were then washed 
and incubated with 400 ng/mL streptavidin–peroxidase for 
30 minutes. After the incubation and wash, 100 µL peroxide–
chromogen solution was added per well, and a SpectraMax 
Plus reader (Molecular Devices, Sunnyvale, CA, USA) was 
used to read at 450 nm. The standard curve was established by 
using mouse recombinant C3a (558618; BD Biosciences).
Immunoresponses to nanoparticles
To evaluate IgM- or IgG-specific response to p5RHH-JNK2 
siRNA nanoparticles, 96-well plates (3855; Immulon 4 HBX; 
Thermo Fisher Scientific) coated with nanoparticles were for-
mulated as previously reported.35 Plates were washed and then 
blocked with 1% BSA in PBS before the addition of diluted 
mouse sera (1:10–1:100 dilution) to wells. After incubation at 
room temperature for 1 hour and washing, HRP-conjugated goat 
antimouse IgM or goat antimouse IgG (1021-05 or 1030-05, 
respectively; Southern Biotechnology Associates, Birmingham, 
AL, USA) antibody was added. After the incubation and wash, 
100 µL peroxide–chromogen solution was added to each well, 
and the SpectraMax Plus reader was used to read at 450 nm.
statistics
Data are represented as means ± standard error (SE). Unpaired 
two-tailed Student’s t-tests were performed to assess differ-
ences between two groups. For comparison between more 
than two groups, one-way analysis of variance (ANOVA) 
followed with Scheffé post hoc test was performed. P,0.05 
was considered statistically significant.
animal study approval
Animal experiments were completed in compliance with US 
federal laws and in accordance with Washington University 
Division of Comparative Medicine guidelines. The animal 
protocol is reviewed annually and approved by the Washington 
University Animal Studies Committee.
Results
p5rhh-JNK2 sirNa decreases plaque 
JNK2 expression in hypercholesterolemic 
apoe-/- mice
In vivo delivery of p5RHH-JNK2 siRNA was tested for 
efficacy by measurements of JNK2 mRNA and protein in 
ApoE-/- mice after seven serial doses administered over 
3.5 weeks, starting at 14 weeks after initiation of a Western 
diet. Compared to controls, which were ApoE-/- mice treated 
with HBSS, JNK2 mRNA levels decreased by 26% in the 
whole aorta from the ApoE-/- mice receiving p5RHH-JNK2 
siRNA nanoparticles (P=0.044; Figure 1A). However, 
p5RHH-scrambled siRNA-nanoparticle treatment over the 
same duration in the age-matched ApoE-/- mice receiving 
the same diet regimen exerted no effect on JNK2 mRNA 
levels (Figure 1A). Moreover, JNK1 mRNA levels were 
not altered by p5RHH-JNK2 siRNA-nanoparticle treatment 
(Figure 1B), thereby confirming isoform specificity of the 
p5RHH-JNK2 siRNA nanoparticles. Because nanoparticles 
packaged with scrambled siRNA did not alter the target 
JNK2 mRNA expression in vivo, ApoE-/- mice receiving 
HBSS treatment served as controls to evaluate in vivo inhi-
bition of JNK2 protein expression and functional effects of 
p5RHH-JNK2-nanoparticle treatments. JNK2 protein levels 
were reduced by 42% in whole aortas from ApoE-/- mice 
receiving p5RHH-JNK2 siRNA nanoparticles compared 
to those in the control group (P=0.042; Figure 1C and D). 
Examples of p5RHH-siRNA nanoparticles residing in plaque 
are illustrated in Figure S2.
JNK2 silencing reduces thrombotic risk
To evaluate the effect of p5RHH-JNK2 siRNA-nanoparticle 
treatment on vessel prothrombotic activity, ApoE-/- mice 
with p5RHH-JNK2 siRNA treatment or HBSS control 
treatment underwent a carotid-artery-injury procedure10,11,32 
to elicit focal clotting, in order to quantify vascular proco-
agulant activity as previously reported. In this widely used 
procedure,36–38 shorter occlusion times indicate more aggres-
sive clotting and heightened thrombotic risk. As illustrated 
in Figure 2A, the time to complete occlusion of siRNA 
nanoparticle-treated ApoE-/- mice increased 200% over 
that of the control subjects (47.2±4.4 vs 22.4±6.8 minutes, 
treated vs control; P=0.02), indicating that even relatively 
short-term therapy with p5RHH-JNK2 siRNA nanoparticles 
dramatically attenuated thrombotic risk.
restoration of endothelial barrier 
function by JNK2 silencing
To probe postulated mechanisms associated with reduced 
thrombotic risk, the status of endothelial vascular barriers in 
ApoE-/- mice receiving p5RHH-JNK2 siRNA-nanoparticle 
treatment or HBSS control treatment was elucidated by 
quantifying the plaque uptake of semipermeating PFC 
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anti-JNK2 sirNa nanoparticles for atherosclerosis
endothelium, but not intact vasculature. As reported 
previously,10,32,39 PFC nanoparticles of nominal 200 nm 
diameter will passively penetrate deeply and rapidly into 
atherosclerotic plaques exhibiting endothelial disruption, 
but are excluded from adjacent vessel regions with intact 
endothelial barriers. Based on the unique 19F MR signature 
of the PFC nanoparticles, absolute quantification of PFC 
nanoparticles accumulating in the plaque components of the 
aorta after 2 hours of in vivo circulation can be calculated 
by registering the 19F MR spectrum and comparing it to a 
known fluorine-calibration standard. Accordingly, quanti-
fication of PFC nanoparticles in the whole aorta provides 
an objective index of vascular barrier disruption. Figure 2B 
illustrates the accumulation of PFC nanoparticles in aortas 
from ApoE-/- mice on a Western diet. Those mice receiving 
p5RHH-JNK2 siRNA nanoparticles manifested a 62% 
reduction in 19F signals emanating from plaque-trapped 
nanoparticles compared to control mice (0.150±0.046 pL/mg 
vs 0.365±0.047 pL/mg for treated vs controls, P=0.003), 
representing a 2.6-fold decrease in barrier permeability and 
disruption after treatment.
JNK2 silencing reduces plaque necrotic 
area and macrophage prevalence
As shown in Figure 2, the acellular plaque area (Figure 2C–E) 
was reduced by 58% (P=0.004), suggesting reduced necrosis. 
Macrophage staining was quantified to define the role of anti-
JNK2 siRNA on plaque-macrophage burden. As demonstrated 
in Figure 2F–H, macrophage populations in the atheroscle-
rotic plaques were reduced significantly in the plaques of 
ApoE-/- mice treated with p5RHH-JNK2 siRNA nanopar-
ticles compared to mice receiving HBSS control treatment.
Figure 1 p5rhh-JNK2 sirNa NPs selectively inhibit JNK2 expression at both mrNa and protein levels in aorta from apoe-/- mice on a Western diet.
Notes: (A) rT2-Pcr results demonstrate the JNK2-mrNa knockdown by p5rhh-JNK2 sirNa NPs (n=7) compared to hBss control (n=6, P=0.044) and p5RHH-scrambled 
sirNa NPs (n=6, P=0.027; one-way aNOVa followed with scheffé post hoc test). (B) JNK1 mrNa expression is not affected by p5rhh-JNK2 sirNa NP treatment (n=6) 
compared to hBss control (n=6). (C and D) Western blot results illustrate JNK2 protein knockdown by p5rhh-JNK2 sirNa NPs (n=5) compared to hBss control (n=6, 
P=0.042; unpaired two-sided Student’s t-test). gaPDh was used as internal control. Data presented in dot plots with means ± se. *P,0.05.
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JNK2 silencing reduces inflammatory 
signaling
Because NFκB signaling is a pivotal driver of inflamma-
tion and a transcriptional mediator of numerous athero-
sclerotic gene families,34,40–42 NFκB-activation status was 
evaluated after p5RHH-JNK2 siRNA-nanoparticle treat-
ment. Immunostaining of p65, a canonical NFκB protein, 
was performed on aorta sections from ApoE-/- mice receiving 
p5RHH-JNK2 siRNA treatment or HBSS control treatment. 
Confocal images on the plaque region revealed significantly 
more cells harboring both cytoplasmic and nuclear p65 in the 
sections from the ApoE-/- mice with HBSS control treatment 
(Figure 3A) than in those treated with the p5RHH-JNK2 
siRNA nanoparticles (Figure 3B). Semiquantification of 
Figure 2 p5rhh-JNK2 sirNa NPs reduce thrombotic risk, restore endothelial integrity, and decrease necrotic plaque area and macrophages.
Notes: (A) shorter occlusion times for untreated apoe-/- mice indicate more aggressive clotting (ie, heightened thrombotic risk) compared to mice treated with p5rhh-
JNK2 sirNa NPs (n=6), which manifest prolonged occlusion times compared to hBss control (n=5, P=0.02). (B) 19F MRS demonstrates significantly less perfluorocarbon 
(ce volume) NP accumulation in apoe-/- mice after p5rhh-JNK2 sirNa NP treatment (n=8) compared to those treated with hBss (n=7) (P=0.003), confirming restoration 
of endothelial barrier integrity that now prohibits passive permeation of perfluorocarbon NPs. (C and D) representative aorta sections demonstrate that necrotic plaque 
area is reduced in p5rhh-JNK2 sirNa NP-treated animals (D) (n=8) compared to those treated with hBss (C) (n=4, bar 100 µm). (E) Necrotic plaque areas from mice 
treated with p5rhh-JNK2 sirNa NPs are reduced compared to mice receiving hBss (P=0.004). (F and G) Representative immunofluorescence stains demonstrate 
significantly fewer Moma-positive cells in atherosclerotic plaque from ApoE-/- mice treated with p5rhh-JNK2 sirNa NPs (G) (n=36) compared to hBss control mice (F) 
(n=17, P,0.001; scale bars: 200 µm). (H) Quantification of Moma-positive cells in the intima. Unpaired two-sided Student’s t-test used for statistical analysis and data 
presented in dot plots with means ± standard error. *P,0.05; **P,0.01; ***P,0.001.
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anti-JNK2 sirNa nanoparticles for atherosclerosis
immunofluorescence-stained sections indicated that 42.66% 
of all cells in plaques from control animals exhibited acti-
vated NFκB signaling, whereas only 22.48% of cells were 
positive in animals undergoing treatment (Figure 3C); a 
47% reduction. Given the cross talk between NFκB and 
STAT343–46 and the crucial role of STAT3 signaling in the 
progression of atherosclerosis,47–49 STAT3 protein expres-
sion in the whole aorta was evaluated (Figure 3D and E). 
p5RHH-JNK2 siRNA nanoparticle-treated animals exhibited 
a 46% reduction in whole-aorta STAT3 expression (P=0.004) 
compared to controls.
effects of p5rhh-JNK2 sirNa on 
macrophages
JNK2 expression has been reported to be two- to threefold 
higher in human atherosclerotic plaques compared to normal 
arteries.50 To define potential cell type(s) that could be 
affected by the local delivery of p5RHH-JNK2 siRNA nano-
particles, the expression of JNK2 within different cell types, 
macrophages, smooth-muscle cells, and endothelial cells was 
evaluated. Costaining of JNK2 and markers for macrophages, 
smooth-muscle cells, and endothelial cells demonstrated 
that macrophages were the principal source of plaque JNK2 
(Figures S3 and S4). Therefore, we evaluated consequences 
of p5RHH-siRNA-nanoparticle treatment of cultured RAW 
264.7 macrophages. To investigate cytoplasmic delivery 
of siRNA to RAW 264.7 cells, Cy3-labeled eGFP siRNA 
nanoparticles were prepared and visualized by confocal 
microscopy. Macrophages were incubated with either 
p5RHH-Cy3-labeled eGFP siRNA nanoparticles or free 
Cy3-labeled eGFP siRNAs for 48 hours before microscopic 
imaging. Surface rendered Z-stack series demonstrated sig-
nificantly more uptake of siRNAs packaged into nanoparticles 
(Figure 4A) than for free Cy3-labeled siRNAs (Figure 4B). 
Moreover, higher-magnification confocal images illus-
trated siRNA endosomal escape and release of siRNAs into 
cytoplasm directly abutting nuclear structures (Figure 4C).
To understand the effects of p5RHH-JNK2 siRNA 
nanoparticles on macrophage JNK2 mRNA and protein 
levels and their role in foam-cell formation, macrophages 
were challenged with acLDL. First, RAW 264.7 cells were 
treated with p5RHH-JNK2 siRNA nanoparticles at siRNA 
concentration of 50 nM and harvested at 24, 48, and 72 hours 
for RNA extraction. Macrophages treated with p5RHH-
JNK2 siRNA nanoparticles after 24, 48, and 72 hours 
exhibited JNK2 mRNA diminution of 79%±3%, 80%±2%, 
and 75%±2%, respectively, vs cells without p5RHH-JNK2 
siRNA-nanoparticle treatment (Figure 5A).
JNK2 protein knockdown was determined at the 72-hour 
time point in macrophages receiving either p5RHH-JNK2 
siRNA nanoparticles, p5RHH-scrambled siRNA nanopar-
ticles, or free JNK2 siRNA, all at siRNA concentration 
Figure 3 p5RHH-JNK2 siRNA NPs reduce inflammatory signaling in atherosclerotic plaque.
Notes: (A and B) Representative confocal images of immunofluorescence stains exhibit reduced nuclear localization of p65 in atherosclerotic plaques from treated ApoE-/- 
mice (B) (n=10) compared to hBss control (A) (n=16, P,0.001). arrows point to cells harboring nuclear p65. Insets highlight cells with (A) and without (B) nuclear p65. 
A and B were captured at magnification of 60×. (C) Quantification of cells with nuclear p65 in plaques. (D and E) Western blot results illustrate sTaT3 protein knockdown 
by p5rhh-JNK2 sirNa NPs (n=5) compared to hBss control (n=6) (P=0.004). GAPDH was used as internal control. Unpaired two-sided Student’s t-test used for statistical 
analysis. **P,0.01; ***P,0.001.
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Figure 4 Delivery of siRNA into RAW 264.7 cells by p5RHH-siRNA nanoparticles.
Notes: (A) Representative confocal images of RAW 264.7 cells in vitro exposed to fluorescently-labeled siRNA (red) nanoparticles reveal abundant cytoplasmic signal 
(imaged at 24 hours after initial exposure). (B) Representative confocal images of RAW 264.7 cells exposed to naked siRNA exhibit little cellular uptake. (C) confocal images 
of individual cells at high magnification show more diffuse cytoplasmic localization, indicating endosomal release of siRNA. Blue, nuclei; red, siRNA. A and B were captured 




Figure 5 p5RHH-JNK2 siRNA NPs inhibit JNK2 expression at both mRNA and protein levels and restrict cellular acLDL uptake in RAW 264.7 cells.
Notes: (A) rT2-Pcr results demonstrate the JNK2 mrNa knockdown by p5rhh-JNK2 sirNa NPs (n=3 per group). (B) Western blotting shows JNK2 protein knockdown 
specifically by p5RHH-JNK2 siRNA NPs but not by p5RHH-scrambled siRNA NPs or free JNK2 siRNA (n=3 per group). (C and D) Knockdown of JNK2 results in prominent 
reduction of lipid accumulation (oil red O staining) in RAW 264.7 cells (D) when incubated with 50 µg/ml aclDl for 12 hours compared to untreated cells (C) (n=4 per 
group). ***P,0.001. C and D were captured at magnification of 4×.
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anti-JNK2 sirNa nanoparticles for atherosclerosis
of 50 nM. Macrophages without treatment served as addi-
tional controls. Only macrophages treated with p5RHH-
JNK2 siRNA nanoparticles manifested significant JNK2 
protein knockdown (Figure 5B).
To assess the functional consequences of JNK2 knock-
down in macrophages, the effect of p5RHH-JNK2 siRNA 
nanoparticles on macrophage acLDL cellular uptake was 
evaluated. RAW 264.7 cells were treated with p5RHH-
JNK2 siRNA nanoparticles at JNK2 siRNA concentration of 
50 nM, and cells without treatment served as controls. After 
48 hours, cells were incubated with 50 µg/mL acLDL for 
another 24 hours, and then oil red O staining was applied to 
delineate cellular uptake of acLDL. Treatment with p5RHH-
JNK2 siRNA nanoparticles substantially inhibited the cel-
lular uptake of acLDL (Figure 5C) compared to controls 
(Figure 5D). These results confirmed that p5RHH-JNK2 
siRNA nanoparticles were capable of decreasing JNK2 
expression at both mRNA and protein levels to inhibit foam-
cell formation.
safety of p5rhh-JNK2 sirNa-
nanoparticle treatment
Blood chemistry, off-target immune-cell functions, and 
innate/adaptive immunoresponses were evaluated. Blood was 
collected after ApoE-/- mice had received serial IV injection 
of seven doses of p5RHH-JNK2 siRNA nanoparticles at 
0.5 mg siRNA/kg over 3.5 weeks, which is the same regimen 
used for therapeutic evaluation. Blood from HBSS-treated 
mice served as control. Blood-chemistry results from the 
serum evaluation are summarized in Table 1, which indicates 
that multiple doses of p5RHH-JNK2 siRNA nanoparticles 
did not alter electrolyte profiles, liver/kidney function, or red 
blood cell/platelet counts.
To evaluate the effect of p5RHH-JNK2 siRNA nano-
particles on the functions of immune cells, 24 hours after 
the last dose, spleens from ApoE-/- mice that had received 
p5RHH-JNK2 siRNA-nanoparticle treatment and the control 
group were harvested for splenocyte-subpopulation analysis. 
As illustrated in Figure 6A, the number of splenocytes was 
significantly lower in ApoE-/- mice treated with p5RHH-
JNK2 siRNA nanoparticles compared to those without treat-
ment (55.00±14×106 vs 94.33±16×106, treated vs control). 
Figure 6B indicates that spleen weights also were 54% lower 
in treated vs HBSS control mice (0.13±0.07 g vs 0.28±0.17 g, 
treated vs control; P=0.001). Moreover, spleen weights in 
treated ApoE-/- mice approximated more those of C57BL/6 
mice on normal chow (0.13±0.07 g vs 0.08±0.01 g, treated 
ApoE-/- mice vs C57BL/6; Figure 6B), and the post-hoc test 
suggested that spleen weights of ApoE-/- mice treated with 
p5RHH-JNK2 siRNA nanoparticles were not significantly 
different from C57BL/6 mice (P=0.511).
Splenocyte-subpopulation differences were examined 
in treated vs untreated ApoE-/- mice: CD8+ and CD4+ T cells, 
FoxP3+ T-regulatory cells, NK1.1+ natural killer cells, and 
GR1+, and CD19+ B cells. Figure 6C depicts the similarity 
between splenocyte subpopulations in these two groups. 
Additionally, following treatment with p5RHH-JNK2 
siRNA nanoparticles, immune-cell function was assessed 
by ex vivo stimulating isolated and purified splenic 
CD4+ T cells with anti-CD3 monoclonal antibody. The 
results (Figure 6D) suggested that under anti-CD3 acti-
vation, CD4+ T cells from control and treated animals 
released comparable amounts of cytokines, including IL10 
(1.72±0.75 vs 0.80±0.12 ng/mL), IL6 (0.106±0.037 vs 
0.04±0.006 ng/mL), TNFα (0.94±0.14 ng/mL vs 0.61±0.04), 
and IFNγ (7.87±0.86 ng/mL vs 6.28±0.50) for treated vs 
control groups, respectively, indicative of preserved immune-
system functionality after anti-JNK2 siRNA treatment.
Host innate immunoresponses to p5RHH-JNK2 siRNA 
nanoparticles were assessed. Plasma from ApoE-/- mice 
was collected 30 minutes after IV injection of HBSS 






rBc (ml/mm2) 9.81±1.51 9.53±0.76
hemoglobin (g/dl) 13.70±2.13 13.65±1.08
hematocrit hc (%) 42.33±7.26 43.40±2.74
Mean corpuscular volume 
(µm3)
43.13±1.52 45.60±1.12
Mean corpuscular hemoglobin 
(pg)
14.00±0.44 14.33±0.05
Mean corpuscular hemoglobin 
concentration (g/dl)
32.43 ±0.50 31.43±0.74
Platelets (thsn/cu mm) 1,151.33±20.60 1,113.75±69.31
BUN (mg/dl) 23.75±3.33 27.50±0.71
creatinine (mg/dl) 0.86±0.29 1.01±0.31
asT (U/l) 102.38±41.76 99.00±29.82
alT (U/l) 50.57±9.03 39.75±10.72
Total protein (g/dl) 10.24±2.65 9.86±3.04
glucose (mg/dl) 283.63±30.09 214.50±48.79
sodium (mmol/l) 144.80±3.3 145.20±2.5
Potassium (mmol/l) 4.6±1.1 4.5±0.5
chloride (mmol/l) 118.6±13.3 117.2±12.0
Notes: *after intravenous injection of seven doses of JNK2 sirNa nanoparticles 
(0.5 mg sirNa/kg) over 23 days. Blood counts: hBss n=3 and p5rhh-JNK2 sirNa 
nanoparticles n=4. Kidney function: HBSS n=8 and p5rhh-JNK2 sirNa nanoparticles 
n=6. liver function: hBss n=8 and p5rhh-JNK2 sirNa nanoparticles n=3. glucose: 
hBss n=8 and p5rhh-JNK2 sirNa nanoparticles n=5. Blood electrolytes: hBss 
n=5 and p5rhh-JNK2 sirNa nanoparticles n=5.
Abbreviations: HBSS, Hanks’ Balanced Salt solution; HC, hematocrit; NP, nano-
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(as control) or p5RHH-JNK2 siRNA nanoparticles for quan-
tification of C3a, a degradation product of C3, which is an in 
vivo indicator of complement activation. As demonstrated in 
Figure 6E, observed was a minimal increase in C3a level in mice 
that received p5RHH-JNK2 siRNA nanoparticles compared 
to HBBS controls (504.86±39.01 vs 339.71±24.61 ng/mL, 
treated vs control). In contrast, Figure 6E indicates that 1,2-
dioleoyloxy-3-(trimethylammonium)propane (DOTAP), 
Figure 6 p5rhh-JNK2 sirNa NPs neither suppress systemic immune-cell function nor induce innate/adaptive immunoresponses.
Notes: (A) After seven sequential doses of p5RHH-siRNA NPs over 3.5 weeks, spleens were extracted and splenocytes enumerated 24 hours after the last dose. ApoE-/-
mice treated with p5rhh-JNK2 NPs (n=4) exhibit significantly fewer splenocytes compared to HBSS control (n=3) (P=0.02). (B) Spleen sizes of mice treated with p5RHH-
JNK2 sirNa NPs (n=19) are significantly smaller than from mice with HBSS treatment (n=12, P=0.001) and approximate spleen sizes of control C57BL/6 mice (n=9, P=0.511; 
one-way aNOVa followed with scheffé post hoc test). (C) Distribution of splenic immune-cell subpopulations was not affected by the p5rhh-JNK2 sirNa NP treatment 
(n=4) compared to HBSS control (n=3; FoxP3+ p5rhh-JNK2 sirNa NP treatment, n=6; hBBs, n=5). (D) Splenic CD4+ T cells stimulated with anti-cD3 monoclonal antibody 
responded normally (hBss, n=5; p5rhh-JNK2 sirNa NPs, n=6). (E) c3a assay indicates that p5rhh-JNK2 sirNa NPs (n=5) do not activate complement (innate immune 
response) compared with DOTaP NPs known to activate strongly (n=5). C3a level of the mice treated with the p5RHH-JNK2 siRNA NPs is significantly smaller than those of 
mice treated with DOTaP NP (P,0.001) and approximates c3a level of hBss control (n=12, P=0.06; one-way aNOVa followed with scheffé post hoc test). (F) IgM and Igg 
specific for serial p5RHH-JNK2 siRNA NP treatment (n=11) were not detected in mouse serum, indicating that treatment does not elicit adaptive immunoresponse (hBss 
control, n=9, unpaired two-sided Student’s t-test used for statistical analysis). Data presented in dot plots with means ± se. *P,0.05; **P,0.01; ***P,0.001.
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a known lipidic complement activator, enhanced C3a 
release and complement activation nearly sixfold (C3a 
2,900.40±91.93 ng/mL), indicative of the relative safety 
margin against immediate immunoresponsiveness.
To evaluate the adaptive immunogenicity of p5RHH-
JNK2 siRNA nanoparticles, IgG- and IgM-antibody responses 
against p5RHH-JNK2 siRNA nanoparticles were evaluated 
after the completion of treatment with seven serial total doses 
over 3.5 weeks (IV administration twice a week). Sera were 
collected from mice that were treated with either p5RHH-JNK2 
siRNA nanoparticles or HBSS, and IgG and IgM antibodies 
specific for p5RHH-JNK2 siRNA nanoparticles were assessed 
by ELISA assays on plates coated with p5RHH-JNK2 siRNA 
nanoparticles. There was no significant difference observed 
between control and treatment groups (Figure 6F), demon-
strating that p5RHH-JNK2 siRNA nanoparticles did not elicit 
appreciable adaptive immunoresponses at these time points.
Discussion
The goal of interfering with macrophage uptake of modified 
lipoproteins seeks to curtail atherosclerosis by removing 
a major stimulus for elaboration of numerous factors that 
perpetuate plaque inflammation. In this report, we describe 
plaque-homing peptide-based siRNA nanoparticles for 
in vivo RNA silencing of critical members of the MAPK-
signaling system (JNK) that focally suppress inflammatory 
drivers of atherosclerotic plaques. Significant new obser-
vations arising from this study were: anti-JNK2 siRNA 
nanoparticles rapidly attenuated thrombotic risk, restored 
endothelial barrier integrity, reduced plaque necrosis, and 
depleted plaque-macrophage content after only a few weeks; 
JNK2 inhibition exerted suppression of proinflammatory 
molecules (eg, NFκB, STAT3); and nanoparticle treatment 
did not compromise critical systemic innate or adaptive 
immunoresponsiveness, and thus the approach exhibits a 
benign safety profile.
JNK2 expression has been reported to be two- to three-
fold higher in human atherosclerotic plaques compared to 
normal arteries.50 ApoE-/-JNK2-/- animals develop fewer 
atherosclerotic plaques, due to suppression of JNK2-
mediated foam-cell formation.16 Moreover, it has been 
reported that enhanced local macrophage proliferation 
caused by scavenger-receptor A-mediated oxLDL uptake 
by macrophages is a key driver of plaque growth.51 In this 
report, focal plaque-macrophage targeting likely resulted from 
endothelial barrier disruption, which occurs in advanced plaques 
prior to neovascularization. In prior studies, we have observed 
no significant plaque angiogenesis at the time points studied in 
this ApoE-/- model,32 which accords with the observations of 
Moulton et al that ApoE-/- mice require at least 6 months on 
a Western diet to develop significant neovascularization.52,53 
Nevertheless, for human atherosclerotic plaques, neovascular-
ization accompanies chronic inflammation,54–59 which might be 
expected to facilitate intimal access via leaky neovasculature 
penetrating from adventitia. Under other experimental condi-
tions, such as collagen antibody-induced arthritis, neovascular 
routes to inflammatory macrophages for p5RHH-siRNA 
nanoparticles may be operative.35
The origin of macrophages in atherosclerotic plaques 
remains an intriguing and debated question.60 Although 
further studies are required to elucidate fully the mechanism 
of the reduction of plaque-macrophage content observed in 
this study, it is possible that both reduced recruitment and 
decreased local proliferation contributed. It has been reported 
that proliferation of local macrophages accounts for most 
of the macrophage population in atherosclerotic plaques51 
and oxLDL uptake promotes macrophage proliferation.61–64 
In light of the fact that JNK2 inhibition is known to reduce 
oxLDL uptake by macrophages,16 Figure 5 (C and D) con-
firms that knockdown of JNK2 with peptide-siRNA nano-
particles in macrophage cell lines significantly decreased 
intracellular accumulation of modified LDL. Because oxLDL 
internalization induces proliferation,61–64 one likely avenue 
for the therapeutic efficacy of p5RHH-JNK2 siRNA pertains 
to reduced local macrophage proliferation (Figure 4A–C). 
The inhibition of JNK2 expression observed in the whole-
aorta protein extracts (Figure 2) is consistent with decreased 
macrophage proliferation. Alternatively, Figure 5 (A and B) 
indicates that treatment reduced spleen size and number of 
splenocytes. It has been reported that monocytes originating 
from the spleen can migrate to plaques and contribute to 
plaque growth as a consequence of local expression of inflam-
matory cytokines/chemokines at atherosclerotic sites.65–67 
Reduced local plaque inflammation might attenuate homing 
signals for splenic monocyte populations.
The anti-inflammatory benefits of this approach are 
suggested by reduced levels of the key STAT3- and NFκB-
signaling pathways. A direct causal relationship between 
JNK2 expression and NFκB/STAT3 signaling is not specified 
by the current observations. It is possible that the JNK2 inhi-
bition engendered an overall downregulation of local inflam-
mation simply by inhibiting foam-cell formation. Indeed, our 
recent work with this siRNA-delivery system for inhibition of 
canonical and noncanonical NFκB in experimental models of 
rheumatism and osteoarthritis indicated that broad suppres-
sion of cytokine/chemokine production by macrophages and 
other activated cell types might be anticipated.35,68 Although it 
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was proatherogenic in LDL-receptor-deficient mice,69 the 
overall modulation of intense inflammatory plaque signal-
ing effected by inhibition of JNK2 in this study appears to 
prevail as a net-positive factor.
RNA silencing for suppressing JNK2-mediated foam-
cell formation rapidly exerts additional benefits for plaque 
healing in the form of improved vascular barrier integrity 
and reduced vascular procoagulant activity. Because endothe-
lial apoptosis promotes thrombosis,70,71 the rapid restoration 
of endothelial barrier integrity observed here lends support 
to mechanistic strategies aimed at preventing endothelial 
apoptosis, enhancing endothelial proliferation, or both. A cor-
relation was observed between endothelial barrier recovery 
and reduced plaque macrophages (Figures 3 and 4).
Although the cellular actions of these siRNA nanostruc-
tures appear to predominate in the local plaque environment, 
there may be responses at a distance. The observation of 
reduced spleen weight after JNK2 inhibition was unexpected, 
but intriguing. The sterile inflammation in the spleen that 
accompanies atherosclerosis has been characterized variously 
as both protective72 and contributory,73 based on the activation 
of selected cellular compartments. We detected no specific 
differences in splenic immune-cell populations (Figure 6) 
in treated or untreated mice, although spleen size differed 
dramatically. Evaluation of immunoactivity toward the 
peptide-nanoparticle agent itself revealed no specific innate 
or adaptive immunoresponses (Figure 6) that might have trig-
gered spleen expansion. Prior work on this peptide-siRNA 
nanoparticle has shown that these transfecting nanoparticles 
are not taken up in the spleen35 and exert no noticeable immu-
noactivation, perhaps militating against direct suppression of 
splenic immunoactivity to effect plaque healing. Moreover, 
body weights in the treated and control mice were similar, 
suggesting that a global effect on inflammation might not 
be operative. Rather, we propose that local resolution of 
plaque inflammation after JNK2 inhibition and the related 
depletion of circulating stimulatory factors within micropar-
ticles and/or exosomes that are released from plaque and 
traffic to distant sites, such as the spleen, could represent an 
alternative mechanism for future exploration. Nevertheless, 
current observations do raise the question of whether splenic 
targeting of JNK2 expression in reservoir macrophages with 
subsequent suppression of activated monocyte trafficking to 
plaques could play a supportive role in improved vascular 
barrier function, reduced procoagulant activity, and plaque 
healing that would be amenable to future study.
The present regimen could be useful for short-term inten-
sive therapies requiring rapid control of hypercoagulable 
plaques under such circumstances as recent non-ST-elevation 
myocardial infarction, unstable angina, refractory angina, 
stroke, and other related pathologies associated with vascular 
barrier disruption and heightened thrombotic risk. Moreover, 
because these nanostructures can be formulated with any 
siRNA or even mixtures of multiplexed oligonucleotides,68 
the approach could serve as a translational test bed for exam-
ining myriad signaling events of interest.
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Supplementary materials
Figure S2 Delivery of sirNa into atherosclerotic plaques with p5rhh-sirNa nanoparticles after intravenous injection in hypercholesterolemic apoe-/- mice (n=3).
Notes: (A) Representative whole-mount IVIS image illustrates siRNA (red) localization along the aorta (left). An aorta from a mouse injected with unlabeled siRNA 
nanoparticles serves as control (right). (B and C). Two-photon images demonstrate the accumulation of sirNa in the plaque intima (B) (red), whereas in the control plaque 
(C), injected with unlabeled siRNA nanoparticles, only autofluorescence (yellow) is observed. The autofluorescent signal in C is shown at amplified gain, due to its weaker 






















Figure S1 carotid-artery photochemical injury to quantify functional procoagulant activity.
Notes: Mice were anesthetized with ketamine (87 mg/kg) and xylazine (37 mg/kg), followed by (1) isolation of the right common carotid artery through a midline cervical 
incision. (2) A Doppler ultrasound probe (Transonic Systems, Ithaca, NY, USA) was placed on the carotid artery to monitor blood-flow rate for the duration of the 
experiment. Mice were (4) administered a dose of 50 mg/kg rose bengal (Sigma-Aldrich, St Louis, MO, USA) saline to initiate thrombus growth following (3) illumination 
of the injury site with a 1.5 mW 540 nm He-Ne laser. The injury procedure concluded upon achieving .85% decrease in measured carotid blood-flow rate maintained 
for .5 minutes, indicative of stable occlusion of the carotid artery. (5) Time to carotid occlusion was measured as a metric of coagulability, where increased time to occlusion 
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Figure S3 representative macrophages in apoe-/- atherosclerotic plaque express JNK2.
Notes: Upper and lower rows are lower- and higher-power images from encircled regions, respectively. Representative fluorescence-microscopy images of JNK2 and 
macrophage costaining of aortas of apoe-/- mice on high-fat diet. (A and D) Overlay images of JNK2 and macrophage costaining; (B and E) JNK2 staining; (C and F) 
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Figure S4 representative smooth-muscle cells and endothelial cells exhibit undetectable JNK2 expression.
Notes: A–C illustrate smooth-muscle-cell costains of aortic sections from apoe-/- on high-fat diets, and D–F illustrate endothelial costains. (A) Overlay images of JNK2/
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